You are here » Home » Companies » Company Overview » Ajanta Pharma Ltd

Ajanta Pharma Ltd.

BSE: 532331	Sector: Health care
NSE: AJANTPHARM	ISIN Code: INE031B01049

BSE 00:00 | 16 May

1683.60

-27.45
(-1.60%)

OPEN

1884.40

HIGH

1884.40

LOW

1664.80

NSE 00:00 | 16 May

1683.40

-29.65
(-1.73%)

OPEN

1722.10

HIGH

1723.00

LOW

1661.55

Add to Watchlist | Add to Portfolio

OPEN	1884.40
PREVIOUS CLOSE	1711.05
VOLUME	2918
52-Week high	2420.00
52-Week low	1593.30
P/E	19.98
Mkt Cap.(Rs cr)	14,378
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	1884.40
CLOSE	1711.05
VOLUME	2918
52-Week high	2420.00
52-Week low	1593.30
P/E	19.98
Mkt Cap.(Rs cr)	14,378
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

Ajanta Pharma Ltd. (AJANTPHARM) - News Sector

USFDA rush after 2-year lull: 20-30% new products may be open to inspection

3.01 am | 16 May 2022 | Business Standard

The last two years saw limited physical inspections due to travel restrictions during the pandemic
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

12.04 am | 14 May 2022 | Business Standard

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
Cipla looks to invest more in mRNA tech; holds discussions with firms

2.03 am | 12 May 2022 | Business Standard

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
Cipla will use Covid-19 bulk drugs inventory when demand rises

11.46 pm | 11 May 2022 | Business Standard

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4

12.27 pm | 11 May 2022 | Business Standard

In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun

8.11 am | 11 May 2022 | Business Standard

Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact

2.26 am | 11 May 2022 | Business Standard

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

1.22 am | 11 May 2022 | Business Standard

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far

11.10 pm | 10 May 2022 | Business Standard

Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
Rainbow Children's Medicare lists at 7% discount to issue price

10.30 am | 10 May 2022 | Business Standard

The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.
75% of Nifty50 stocks trade below 200-DMA; look weak on the charts

11.43 pm | 6 May 2022 | Business Standard

Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so fa...
Sanofi India: Strong balance sheet, high cash reserves positives for stock

12.29 am | 6 May 2022 | Business Standard

Products in the price control list and growth of the non-power brand portfolio will be key monitorables
Pfizer sets up drug development centre at Chennai's IIT Research Park

9.34 am | 5 May 2022 | Business Standard

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technolog...
Zomato, L&T Infotech, Solara, TTML plunge over 25% in one month

11.47 am | 4 May 2022 | Business Standard

Shares of Zomato hit a new low of Rs 64.70, down 7 per cent on the BSE in Wednesday's intra-day trade
Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow

7.02 pm | 2 May 2022 | Business Standard

During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals
Solara Active Pharma slips 15% after Rajender Rao resigns as MD & CEO

11.21 am | 2 May 2022 | Business Standard

Jitesh Devendra, former CEO and Managing Director (MD) of the company will return to Solara as MD, to steer the reset strategy of the Company
Gland Pharma advances 9% on heavy volumes; stock hits 9-week high

12.18 pm | 21 Apr 2022 | Business Standard

At 09:15 AM; around 5.42 million equity shares, representing 3.3 per cent of total equity of Gland Pharma, changed hands on the BSE
Cost pressure likely to weigh on pharma companies' margins in Q4

12.50 am | 20 Apr 2022 | Business Standard

Among Indian firms, Edelweiss feels that Cipla (respiratory) and Sun Pharma (specialty) are better placed to tide the price erosion
Growth trajectory, margins anc client additions to sustain for Laurus Labs

10.49 pm | 19 Apr 2022 | Business Standard

Some of the growth is captured in the price rally, higher valuations
Sanofi India names Rodolfo Hrosz managing director effective June 1

6.58 pm | 18 Apr 2022 | Business Standard

He will transition from being Sanofi's GM, Consumer Healthcare business in Brazil to the new role in India as soon as regulatory approvals are in plac...